Response to twice-daily subcutaneous bolus injections of deferoxamine: update of old and new cases
Patient no.* . | Diagnosis . | Age, y/sex . | Initial ferritin level, μg/L† . | TIL before chelation, mg/kg‡ . | TIL during chelation, mg/kg‡ . | UIE after DFO bolus, μg/48 h . | UIE after DFO infusion, μg/48 h . | Follow-up time, mo . | Last ferritin value, μg/L . |
|---|---|---|---|---|---|---|---|---|---|
| 4 | IMF | 61/M | 2100 | 261.0 | 316.1 | 7880 | 11 530 | 74 | 816 |
| 6 | CML, CP | 48/F | 1670 | 195.8 | 427.2 | 13 000 | 11 390 | 79 | 550 |
| 7 | NHL, LG | 77/F | 1130 | 95.2 | 419.0 | 4144 | 3737 | 78 | 670 |
| 8 | MDS, RA | 51/F | 685 | 89.8 | 422.7 | 7703 | 6790 | 81 | 522 |
| 17 | MDS, RAS | 63/F | 2153 | 232.0 | 360.5 | 11 050 | 13 480 | 72 | 1120 |
| 28 | MDS, RA | 57/F | 1466 | 110.7 | 192.0 | 8728 | 10 218 | 38 | 710 |
| 29 | MDS, RAEB-t | 76/M | 3592 | 255.1 | 158.4 | 4256 | 2880 | 35 | 1912 |
| 30 | MDS, RA | 45/M | 1875 | 129.4 | 118.4 | 11 010 | 8860 | 21 | 1235 |
| 31 | MDS, RA | 64/M | 2510 | 174.0 | 94.1 | 7010 | 3900 | 12 | 1930 |
| 32 | MDS, RAEB | 63/F | 829 | 83.1 | 126.7 | 9870 | 13 220 | 26 | 435 |
| 33 | MDS, RAEB | 59/M | 1254 | 96.7 | 101.3 | 6190 | 5310 | 13 | 630 |
| 34 | RCA | 55/F | 781 | 77.0 | 226.1 | 3330 | 3412 | 51 | 432 |
| Mean (± SD) | 1670.3 (± 843.9) | 150.0 (± 70.1) | 246.9 (± 134.0) | 7847.6 (± 3047.6) | 7893.9 (± 4019.3) | 46.8 (± 28.9) | 913.5 (± 532.0) |
Patient no.* . | Diagnosis . | Age, y/sex . | Initial ferritin level, μg/L† . | TIL before chelation, mg/kg‡ . | TIL during chelation, mg/kg‡ . | UIE after DFO bolus, μg/48 h . | UIE after DFO infusion, μg/48 h . | Follow-up time, mo . | Last ferritin value, μg/L . |
|---|---|---|---|---|---|---|---|---|---|
| 4 | IMF | 61/M | 2100 | 261.0 | 316.1 | 7880 | 11 530 | 74 | 816 |
| 6 | CML, CP | 48/F | 1670 | 195.8 | 427.2 | 13 000 | 11 390 | 79 | 550 |
| 7 | NHL, LG | 77/F | 1130 | 95.2 | 419.0 | 4144 | 3737 | 78 | 670 |
| 8 | MDS, RA | 51/F | 685 | 89.8 | 422.7 | 7703 | 6790 | 81 | 522 |
| 17 | MDS, RAS | 63/F | 2153 | 232.0 | 360.5 | 11 050 | 13 480 | 72 | 1120 |
| 28 | MDS, RA | 57/F | 1466 | 110.7 | 192.0 | 8728 | 10 218 | 38 | 710 |
| 29 | MDS, RAEB-t | 76/M | 3592 | 255.1 | 158.4 | 4256 | 2880 | 35 | 1912 |
| 30 | MDS, RA | 45/M | 1875 | 129.4 | 118.4 | 11 010 | 8860 | 21 | 1235 |
| 31 | MDS, RA | 64/M | 2510 | 174.0 | 94.1 | 7010 | 3900 | 12 | 1930 |
| 32 | MDS, RAEB | 63/F | 829 | 83.1 | 126.7 | 9870 | 13 220 | 26 | 435 |
| 33 | MDS, RAEB | 59/M | 1254 | 96.7 | 101.3 | 6190 | 5310 | 13 | 630 |
| 34 | RCA | 55/F | 781 | 77.0 | 226.1 | 3330 | 3412 | 51 | 432 |
| Mean (± SD) | 1670.3 (± 843.9) | 150.0 (± 70.1) | 246.9 (± 134.0) | 7847.6 (± 3047.6) | 7893.9 (± 4019.3) | 46.8 (± 28.9) | 913.5 (± 532.0) |
UIE indicates urinary iron excretion; IMF, idiopathic myelofibrosis; MDS, myelodysplastic syndrome; RA, refractory anemia; RAS, refractory anemia with ring sideroblasts; RAEB, refractory anemia with excess of blast cells; RAEB-t, refractory anemia with excess of blast cells in transformation to AML; CML, chronic myeloid leukemia; CP, chronic phase; NHL, non-Hodgkin lymphoma; LG, low grade; TIL, transfusional iron load; and RCA, red cell aplasia.
Patient nos. 4, 6, 7, 8, 17 are old cases; patient nos. 28-34 are new cases.
Normal range of serum ferritin concentration: 15 μg/L to 250 μg/L.
Transfusional iron load (TIL) before chelation therapy (expressed as the total amount of iron transfused per kilogram of body weight) and TIL during chelation therapy (expressed as the total amount of iron transfused during the follow-up time [months] per kilogram of body weight).